Opiant Pharmaceuticals
445 Park Ave Floor 9
New York
New York
10022-8606
United States
105 articles about Opiant Pharmaceuticals
-
Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update
11/12/2020
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reported financial results for the three months ended September 30, 2020, and provided a corporate update.
-
Opiant Pharmaceuticals to Participate at the Jefferies 2020 Virtual London Healthcare Conference
11/2/2020
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, is scheduled to present its pipeline at the Jefferies 2020 Virtual London Healthcare Conference on Thursday, November 19th, 2020, at 6:45 pm GMT.
-
Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment
10/29/2020
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma (“Aptar”), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar’s Unit Dose System (UDS) for the treatment of opioid overdose.
-
Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
10/27/2020
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its third quarter 2020 financial results after the financial markets close on Thursday November 12, 2020.
-
Opiant Pharmaceuticals to Participate at the 2020 Cantor Global Virtual Healthcare Conference
8/31/2020
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, is scheduled to participate in a fireside chat to discuss its pipeline of products for addiction and overdose at the Cantor Global Virtual Healthcare Conference
-
Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update
8/6/2020
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reported financial results for the three months ended June 30, 2020, and provided a corporate update.
-
Opiant Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
7/23/2020
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its second quarter 2020 financial results after the financial markets close on Thursday August 6, 2020.
-
Opiant Pharmaceuticals to Present at the 2020 Jefferies Virtual Healthcare Conference
5/26/2020
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, will present a company overview at the Jefferies Virtual Healthcare Conference
-
Opiant Pharmaceuticals to Hold Virtual 2020 Annual Shareholder Meeting
5/21/2020
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it is changing the format of its 2020 annual meeting of shareholders (the “2020 Annual Meeting”)
-
Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update
5/12/2020
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reported financial results for the three months ended March 31, 2020, and provided a corporate update.
-
Opiant Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on Tuesday, May 12
4/28/2020
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the first quarter ended March 31, 2020, after the market close and host a corporate update conference call and webcast on Tuesday, May 12, at 4:30 p.m. Eastern Time. Conference Call Details: Tuesday, May 12 th at 4:30
-
Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
3/4/2020
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the fourth quarter and year ended December 31, 2019, and provided a corporate update.
-
Opiant Pharmaceuticals to Report Fourth Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, March 4
2/24/2020
SANTA MONICA, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2019, after the market close, and will host a corporate update conference call and webcast on Wednesday, March 4, at 4:30 p.m. Eastern Time. Conference Call Details: Wed
-
Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose
1/2/2020
This collaboration will be carried out under a Cooperative Research and Development Agreement between Opiant and the NIH.
-
Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research & Development Authority for Development of OPNT003 for the Treatment of Opioid Overdose
12/12/2019
Opiant intends to pursue a 505(b)(2) development path for OPNT003 and anticipates the potential to submit a New Drug Application for the drug and intranasal delivery device combination in the fourth quarter 2020.
-
Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/12/2019
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reported financial results for the third quarter and nine months ended September 30, 2019, and provided a corporate update.
-
Opiant Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on Tuesday, November 12
11/5/2019
Opiant Pharmaceuticals, Inc. announced that it will report its financial results for the third quarter and nine months ended September 30, 2019, after the market close, and will host a corporate update conference call and webcast on Tuesday, November 12, at 4:30 p.m. Eastern Time.
-
Opiant Pharmaceuticals to Host a Research & Development Meeting on Emerging Therapeutics for the Treatment of Addiction and Drug Overdose
10/10/2019
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that Chief Executive Officer, Roger Crystal, M.D., and Chief Scientific Officer, Phil Skolnick, Ph.D., D.Sc. (hon.), will provide an in-depth review of Opiant's most advanced programs for treating addiction and drug overdose, on Thursday, October 17th in New York City at 12:00 pm ET.
-
Opiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of Acute Cannabinoid Overdose
7/23/2019
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced that it has signed an agreement with Sanofi to manufacture Opiant’s investigational agent OPNTOO4 for the treatment of Acute Cannabinoid Overdose.
-
Shares of Opiant Pharmaceuticals fell in trading Thursday and continue to slide in premarket trading this morning after the company announced its Phase II trial evaluating a naloxone nasal spray for the treatment of bulimia nervosa failed to meet primary endpoints and will discontinue the program.